Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
Stay ahead with the latest insights! Download DelveInsight's comprehensive Relapsing-Remitting Multiple Sclerosis Pipeline Report to explore emerging therapies, key Relapsing-Remitting Multiple Sclerosis Companies, and future Relapsing-Remitting Multiple Sclerosis treatment landscapes @ Relapsing-Remitting Multiple Sclerosis Pipeline Outlook Report
Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report
In June 2025, Novartis Pharmaceuticals announced a study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab.
In June 2025, Celgene conducted a study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
DelveInsight's Relapsing-Remitting Multiple Sclerosis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment.
The leading Relapsing-Remitting Multiple Sclerosis Companies such as Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Promising Relapsing-Remitting Multiple Sclerosis Therapies such as TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others.
Discover how the Relapsing-Remitting Multiple Sclerosis treatment paradigm is evolving. Access DelveInsight's in-depth Relapsing-Remitting Multiple Sclerosis Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing-Remitting Multiple Sclerosis Clinical Trials and Studies
Relapsing-Remitting Multiple Sclerosis Emerging Drugs Profile
IMU-838: Immunic AG
Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Currently, the drug is in Phase III stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
IMCY-0141: Imcyse SA
IMCY-0141 Imotope™ is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
ANK-700: Anokion SA
ANK-700 is an investigational therapy developed by Anokion for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). It employs a novel approach known as an ""inverse vaccine,"" aiming to re-educate the immune system to recognize specific myelin proteins as ""self,"" thereby preventing autoimmune attacks on the central nervous system. This strategy seeks to reduce neuroinflammation while preserving overall immune function. Anokion's approach utilizes its proprietary immune tolerance platform, which targets natural pathways in the liver to restore immune tolerance. This liver-targeted antigen strategy effectively expands antigen-specific regulatory T-cells in vivo, offering therapeutic potential across various inflammatory conditions, including multiple sclerosis. ANK-700's innovative mechanism and encouraging early clinical data position it as a promising candidate for future disease-modifying therapies in RRMS. Currently, the drug is in Phase I stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis.
The Relapsing-Remitting Multiple Sclerosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing-Remitting Multiple Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing-Remitting Multiple Sclerosis Treatment.
Relapsing-Remitting Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Relapsing-Remitting Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing-Remitting Multiple Sclerosis market.
Get a detailed analysis of the latest innovations in the Relapsing-Remitting Multiple Sclerosis pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing-Remitting Multiple Sclerosis Unmet Needs
Relapsing-Remitting Multiple Sclerosis Companies
Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Relapsing Remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Relapsing-Remitting Multiple Sclerosis Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Relapsing-Remitting Multiple Sclerosis Therapies and key Relapsing-Remitting Multiple Sclerosis Developments @ Relapsing-Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives
Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report
Coverage- Global
Relapsing-Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others.
Relapsing-Remitting Multiple Sclerosis Therapies- TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others.
Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Relapsing-Remitting Multiple Sclerosis drug development? Find out in DelveInsight's exclusive Relapsing-Remitting Multiple Sclerosis Pipeline Report—access it now! @ Relapsing-Remitting Multiple Sclerosis Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Relapsing-Remitting Multiple Sclerosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Relapsing-Remitting Multiple Sclerosis– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
IMU-838: Immunic AG
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Telitacicept: RemeGen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ANK700: Anokion
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Relapsing-Remitting Multiple Sclerosis Key Companies
Relapsing-Remitting Multiple Sclerosis Key Products
Relapsing-Remitting Multiple Sclerosis- Unmet Needs
Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers
Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion
Relapsing-Remitting Multiple Sclerosis Analyst Views
Relapsing-Remitting Multiple Sclerosis Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/relapsing-remitting-multiple-sclerosis-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
17 minutes ago
- Cision Canada
Full Circle Lithium Announces Non-Brokered Private Placement for Gross Proceeds of C$3 Million
, Aug. 15, 2025 /CNW/ - Full Circle Lithium Corp. ("FCL" or the "Company") (TSXV: FCLI) (OTCQB: FCLIF), a USA-based lithium products manufacturer, is pleased to announce that it has entered into an agreement with PowerOne Capital Markets Limited PowerOne to act as the Lead Finder in connection with a non-brokered private placement (the "Offering") for aggregate gross proceeds of up to C$3,000,000 from the sale of up to 15,000,000 units of the Company (the "Units") at a price of C$0.20 per Unit (the "Offering Price"). Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant of the Company (each whole warrant, a "Warrant"). Each Warrant shall entitle the holder to purchase one additional common share of the Company at a price of C$0.30 at any time on or before the date which is 24 months after the Closing date (as defined below), subject to acceleration in the event the closing price of the common shares it at least $0.80 for a period of not less than 20 consecutive trading days. The Offering is being made to purchasers in Canada pursuant to the listed issuer financing exemption (the "LIFE") under Part 5A of National Instrument 45-106 -Prospectus Exemptions ("NI 45-106"). The securities issued under the Offering will not be subject to a hold period in accordance with applicable Canadian securities laws. The Offering will also be conducted in the United States and certain foreign jurisdictions pursuant to applicable regulatory requirements and in accordance with OSC Rule 72-503 - Distributions Outside Canada. There is an offering document related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective Canadian investors should read this offering document before making an investment decision. The Company expects to use the net proceeds of the Offering for product development, intellectual property protection, training centre development and working capital requirements. Closing of the Offering is expected to occur on or about August 27, 2025 or such other date as the Company may decide and remains subject to the Company obtaining all necessary corporate and regulatory approvals, including approval of the TSXV. The Company may pay finders' fees in connection with the Offering and in accordance with the policies of the TSXV. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release. Such securities have not been, and will not be, registered under the U.S. Securities Act, or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or "U.S. Persons", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements. About Full Circle Lithium Corp. FCL has developed an innovative lithium-ion battery fire-extinguishing agent named FCL-X™ to address the increasing number of difficult-to-extinguish and hazardous lithium-ion battery-based fires. FCL-X™ is a non-hazardous fire extinguishing agent specifically designed to combat lithium-ion cell and/or battery fires. A water-based solution, FCL-X™ has been tested by 3 rd party laboratories as well as on live battery fires, on both small and industrial scale fires, and has proved that it mitigates the lithium oxidation reaction, limiting hydrogen generation and stabilizing decomposing electrolytes. FCL-X™ is easy to use, with fast heat dissipation, minimal clean-up, and non-hazardous properties, making it a sustainable choice. FCL has gathered a leading technical team with over 100 years of combined lithium, fire, and safety training and firefighting experience. Additional information regarding FCL is available on SEDAR at under the Company's profile and on its website For further information: Full Circle Lithium Corp. Carlos Vicens - CEO & Director [email protected] +1.416.977.3832 Cautionary Statement Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. This news release contains forward-looking statements within the meaning of securities legislation in the Canada and which are based on the expectations, estimates and projections of management of the parties as of the date of this news release unless otherwise stated. Forward-looking statements are generally identifiable by use of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "could", "believe", "plans", "intends" or the negative of these words or other variations on these words or comparable terminology. More particularly, and without limitation, this news release contains forward-looking statements and information concerning expectations on the effectiveness of the marketing and sales of FCL-X™ through distribution agreements, the viability, effectiveness, safety and additional commercialization related to FCL-X™ which is at an early stage of commercialization (which is very difficult for a start-up venture like FCL as there are much larger and better capitalized established companies that can potentially quickly enter the lithium-ion battery fire-fighting market and create strong competition against FCL), on receiving patent protection for FCL-X™ and related inventions and processes, the ability of FCL, a start-up venture, to successfully commercialize its FCL-X™ including ramping-up production of the agent to meet potential demand, continue raising capital, upgrading and refurbishing its plant, and sourcing feedstock for this and its other lines of business. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, the uncertainties and risk factors related to the technical elements in a processing and refining business, loss of key technical and other staff, lithium price fluctuations, the battery fire-extinguishing agent functioning as expected to meet safety requirements and fire-fighting related government regulations and potential client product specifications, and applicable environmental requirements and issues – see additional risks described in FCL's public filings. Actual results, developments and timetables could vary significantly from the estimates presented. Readers are cautioned not to put undue reliance on forward-looking statements. FCL disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. Additionally, FCL undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of FCL, its financial or operating results or its securities.
Globe and Mail
17 minutes ago
- Globe and Mail
American Integrity Insurance Group Surpasses 400,000 Policies In-force, Marking a Major Post-IPO Milestone
American Integrity Insurance Group, Inc. (NYSE: AII) ('American Integrity' or the 'Company'), a Tampa-based property and casualty insurance holding company and one of Florida's leading providers of residential property insurance, announced today that it has surpassed 400,000 policies in-force—a historic milestone for the Company and a powerful signal to the market. The achievement comes just weeks after the Company's successful initial public offering and listing on the New York Stock Exchange and underscores the Company's momentum, market trust, and long-term growth trajectory. 'This is more than a number—it's a statement,' said Bob Ritchie, Founder and Chief Executive Officer of American Integrity. 'Surpassing 400,000 policies reflects the grit, execution, and values-driven culture that have powered our journey from day one. It tells our customers, our distribution partners, and our investors that we're not just growing—we're building something enduring.' The milestone reinforces American Integrity's role as a market leader in Florida's challenging property insurance landscape. With strong underwriting discipline, deep reinsurance partnerships, and a focus on service excellence, the Company continues to scale responsibly and profitably. 'We've always believed our strength comes from something deeper than capital,' Ritchie added. 'It comes from integrity. That's the core of who we are—and it's resonating louder than ever.' About American Integrity Insurance Group, Inc. American Integrity Insurance Group, Inc. (NYSE: AII) is a leading provider of residential property insurance, focused on delivering innovative, reliable coverage to homeowners throughout Florida. Built on a foundation of integrity, resilience, and service, the Company's mission is to be the most trusted and responsive insurance solution in the markets it serves. Founded in 2006 and headquartered in Tampa, American Integrity is committed to protecting policyholders with strength and purpose—today and for generations to come.
Globe and Mail
27 minutes ago
- Globe and Mail
Analysts Offer Insights on Technology Companies: Cisco Systems (CSCO) and Palo Alto Networks (PANW)
There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Cisco Systems (CSCO – Research Report) and Palo Alto Networks (PANW – Research Report) with bullish sentiments. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cisco Systems (CSCO) In a report released today, Michael Genovese from Rosenblatt Securities reiterated a Buy rating on Cisco Systems, with a price target of $87.00. The company's shares closed last Wednesday at $70.40. According to Genovese is a 5-star analyst with an average return of 12.2% and a 53.2% success rate. Genovese covers the Technology sector, focusing on stocks such as Applied Optoelectronics, Ribbon Communications, and Lumentum Holdings. ;'> Cisco Systems has an analyst consensus of Moderate Buy, with a price target consensus of $74.07, a 3.1% upside from current levels. In a report issued on July 31, J.P. Morgan also maintained a Buy rating on the stock with a $78.00 price target. Palo Alto Networks (PANW) In a report released today, Catharine Trebnick from Rosenblatt Securities maintained a Buy rating on Palo Alto Networks, with a price target of $215.00. The company's shares closed last Wednesday at $176.86. According to Trebnick 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.9% and a 38.3% success rate. Trebnick covers the Technology sector, focusing on stocks such as Zoom Video Communications, CrowdStrike Holdings, and CyberArk Software. ;'> The word on The Street in general, suggests a Strong Buy analyst consensus rating for Palo Alto Networks with a $215.73 average price target, implying a 19.8% upside from current levels. In a report issued on August 12, Piper Sandler also upgraded the stock to Buy with a $225.00 price target.
